Meeting
2015 ASCO Annual Meeting
Impact of a Stage IV NSCLC care pathway on front-line (FL) and maintenance (M) chemotherapy use at the Cleveland Clinic Taussig Cancer Institute (TCI).
Authors
Marc A. Shapiro
Cleveland Clinic, Cleveland, OH
Marc A. Shapiro , James Stevenson , Emily Van Wagoner , Katherine Glass , Chad W Cummings , Nathan A. Pennell , Patrick C. Ma , Vamsidhar Velcheti , Bruno R. Bastos , Brian James Bolwell , Abdo Haddad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 33, 2015 (suppl; abstr 6609)
DOI
10.1200/jco.2015.33.15_suppl.6609
Abstract #
6609
Poster Bd #
166
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Circulating tumor DNA to guide furmonertinib monotherapy or combination therapy in advanced EGFR mutant non-small cell lung cancer (NSCLC): A randomized, open-label, multicenter study (FOCUS-C).
First Author: Wenfeng Fang
Poster
2020 ASCO Virtual Scientific Program
A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).
First Author: Sehhoon Park
Poster
2019 ASCO Annual Meeting
ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).
First Author: Myung-Ju Ahn
Poster
2024 ASCO Annual Meeting
Survival outcomes and subgroup analyses derived from a phase III randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834).
First Author: Yuki Sato